Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi !

PHARMACOGENOMICS OF ANASTRAZOLE COULD PREDICT INTERPATIENT VARIABILITY IN THE INTENSITY OF ADVERSE EFFECTS (CROSBI ID 639140)

Prilog sa skupa u zborniku | sažetak izlaganja sa skupa | međunarodna recenzija

Bojanić, Kristina ; Kizivat, Tomislav ; Kuna, Lucija ; Wagner, Jasenka ; Smolić, Robert ; Božić, Ivana ; Mršo, Margareta ; Raguž-Lučić, Nikola ; Včev, Aleksandar ; Smolić, Martina PHARMACOGENOMICS OF ANASTRAZOLE COULD PREDICT INTERPATIENT VARIABILITY IN THE INTENSITY OF ADVERSE EFFECTS. 2015. str. 1-1

Podaci o odgovornosti

Bojanić, Kristina ; Kizivat, Tomislav ; Kuna, Lucija ; Wagner, Jasenka ; Smolić, Robert ; Božić, Ivana ; Mršo, Margareta ; Raguž-Lučić, Nikola ; Včev, Aleksandar ; Smolić, Martina

engleski

PHARMACOGENOMICS OF ANASTRAZOLE COULD PREDICT INTERPATIENT VARIABILITY IN THE INTENSITY OF ADVERSE EFFECTS

Anastrozole is a selective competitive aromatase inhibitor (AI) widely used as adjuvant treatment for early stage breast cancer. Phase I metabolism of anastrazole involves N-dealkylation by CYP3A4 and CYP3A5 , whereas phase II predominantly involves glucuronidation by UGT1A4.The most common adverse events of AIs are osteoporosis and musculosceletal events, whereas hepatotoxicity is less frequent.To elucidate genetic polymorphism of enzymes involved in anastrazole metabolism and determine the role of CYP3A4, CYP3A5 and UGT1A4 pharmacogenomics in the interindividual variations in anastrazole metabolism and the intensity of adverse effects. Osteopenia was found in 34% and osteoporosis in 17% of participants. The cumulative incidence of NAFLD was 24.6%in the study group. However, the correlation in the interpatient variability in the intensity of hepatotoxicity or osteoporosis to functional genetic polymorphisms studiedwas not found. The intensity of adverse effects plays an essential part in maintaining patient complience to anastrazole therapy. Functional genetic polymorphisms of enzymes involved in anastrazole metabolism could be correlated to altered aromatase activity, disease prognosis and severity of aromatase inhibitor adverse effects, however large genotyping studies are obligatory.

anastrozole ; breast cancer osteoporosis ; pharmacogenomics

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o prilogu

1-1.

2015.

nije evidentirano

objavljeno

Podaci o matičnoj publikaciji

Podaci o skupu

9th ISABS Conference on Forensic and Anthropologic Genetics and Individualized Medicine

poster

22.06.2015-26.06.2015

Bol, Hrvatska

Povezanost rada

Temeljne medicinske znanosti